Cipher Pharmaceuticals (TSE:CPH)
TSX:CPH
Want to see TSE:CPH full AI Analyst Report?
CPH Stock Chart & Stats
C$14.90
C$0.11(0.75%)
At close: 4:00 PM EST
C$14.90
C$0.11(0.75%)
Day’s Range― - ―
52-Week RangeC$11.87 - C$19.63
Previous CloseN/A
Volume17.82K
Average Volume (3M)26.25K
Market Cap
C$466.94M
Enterprise ValueC$341.48M
Total Cash (Recent Filing)C$7.48M
Total Debt (Recent Filing)C$5.49M
Price to Earnings (P/E)10.1
Beta0.43
Next Earnings
May 07, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding25,281,181
10 Day Avg. Volume28,238
30 Day Avg. Volume26,255
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.22
Price to Sales (P/S)5.44
P/FCF Ratio9.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$21.00Price Target Upside40.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.63
Revenue Forecast (FY)C$54.52M
Bulls Say, Bears Say
Bulls Say
Cash Generation QualityConsistent and growing operating and free cash flow demonstrates durable cash conversion from operations, supporting reinvestment, debt servicing and optionality for M&A or product launches. Strong cash generation reduces financing risk and underpins sustainable capital allocation over the next 2–6 months and beyond.
Accelerating Revenue TrendSharply accelerating top-line growth across consecutive years signals expanding product adoption and commercial traction. Sustained revenue momentum increases operating leverage potential and provides a stronger base to sustain margins and fund new launches, improving predictability of medium-term cash flows.
Focused Commercial ModelOwning Canadian commercialization lets Cipher capture higher-margin direct sales while licensing internationally conserves capital and scales reach. This hybrid model balances margin capture with low-capex geographic expansion, supporting durable revenue diversification and efficient use of a small commercial organization.
Bears Say
Earnings And Margin VolatilityMarked year-to-year swings in reported profitability reduce confidence in forward earnings predictability and complicate planning. Volatility can reflect lumpy items, product lifecycle effects, or one-offs, making margin sustainability and forecasting less reliable for investors and management over the medium term.
Capital Structure Instability (2024)A meaningful, though temporary, debt spike creates uncertainty about financing discipline or one-off funding needs. Episodic leverage increases can strain covenants or raise refinancing risk if repeated, and they reduce clarity on long-term capital structure policy and cost of capital for strategic initiatives.
Partner Execution And Geographic RiskReliance on external partners for international commercialization exposes revenue to partner execution, pricing, and reimbursement dynamics. If partners underperform or regulatory/reimbursement conditions change, royalty streams and milestone timing can be delayed or reduced, weakening medium-term revenue visibility.
Cipher Pharmaceuticals News
CPH FAQ
What was Cipher Pharmaceuticals’s price range in the past 12 months?
Cipher Pharmaceuticals lowest stock price was C$11.87 and its highest was C$19.63 in the past 12 months.
What is Cipher Pharmaceuticals’s market cap?
Cipher Pharmaceuticals’s market cap is C$466.94M.
When is Cipher Pharmaceuticals’s upcoming earnings report date?
Cipher Pharmaceuticals’s upcoming earnings report date is May 07, 2026 which is in 9 days.
How were Cipher Pharmaceuticals’s earnings last quarter?
Cipher Pharmaceuticals released its earnings results on Mar 12, 2026. The company reported C$0.695 earnings per share for the quarter, beating the consensus estimate of C$0.211 by C$0.484.
Is Cipher Pharmaceuticals overvalued?
According to Wall Street analysts Cipher Pharmaceuticals’s price is currently Undervalued.
Does Cipher Pharmaceuticals pay dividends?
Cipher Pharmaceuticals does not currently pay dividends.
What is Cipher Pharmaceuticals’s EPS estimate?
Cipher Pharmaceuticals’s EPS estimate is 0.18.
How many shares outstanding does Cipher Pharmaceuticals have?
Cipher Pharmaceuticals has 25,281,181 shares outstanding.
What happened to Cipher Pharmaceuticals’s price movement after its last earnings report?
Cipher Pharmaceuticals reported an EPS of C$0.695 in its last earnings report, beating expectations of C$0.211. Following the earnings report the stock price went up 17.198%.
Which hedge fund is a major shareholder of Cipher Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:CPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cipher Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$21.00 (40.94% Upside)
C$21.00 (40.94% Upside)
Insider Transactions
Sold Shares
Worth C$129.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.29%
12-Months-Change
Fundamentals
Return on Equity
24.23%
Trailing 12-Months
Asset Growth
-3.70%
Trailing 12-Months
Company Description
Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
CPH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and significant debt reduction, supported by the robust performance of the Natroba business. However, challenges remain in licensing revenue and the Absorica portfolio, along with increased SG&A costs. Overall, the positive aspects slightly outweigh the negative aspects.View all TSE:CPH earnings summariesCPH Stock 12 Month Forecast
Average Price Target
C$21.00
▲(40.94% Upside)
Technical Analysis
Knight Therapeutics
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―
Options Prices
Currently, No data available
---